Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells

Regulatory Peptides

Volumn 144, Issue 1-3, 2007, Pages 101-108

  Valdehita, Ana ^a   Carmena, María J ^a   Collado, Beatriz ^a   Prieto, Juan C ^a   Bajo, Ana M ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Angiogenesis; Breast cancer; cAMP; VEGF expression; VIP

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; VASCULOTROPIN; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2; WORTMANNIN;

ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; FEMALE; GENE EXPRESSION; HUMANS; RNA, MESSENGER; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASOACTIVE INTESTINAL PEPTIDE;

EID: 35649010378     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2007.06.006     Document Type: Article

References (53)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., and Thun M.J. Cancer statistics. CA Cancer J Clin 56 (2006) 106-130
2. Abba M.C., Drake J.A., Hawkins K.A., Hu Y., Sun H., Notcovich C., Gaddis S., Sahin A., Baggerly K., and Aldaz C.M. Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Res 6 (2004) 499-513
3. Schally A.V., Comaru-Schally A.M., Nagy A., Kovacs M., Szepeshazi K., Plonowski A., Varga J., and Halmos G. Hypothalamic hormones and cancer. Front Neuroendocrinol 22 (2001) 248-291
4. Vogl G., Dietze O., and Hauser-Kronberger C. Angiogenic potential of ductal carcinoma in situ (DCIS) of human breast. Histopathology 47 (2005) 617-624
5. Boudreau N., and Myers C. Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res 5 (2003) 140-146
6. Pintucci G., Bikfalvi A., Klein S., and Rifkin D.B. Angiogenesis and the fibrinolytic system. Semin Thromb Hemost 22 (1996) 517-522
7. Donovan E.A., and Kummar S. Targeting VEGF in cancer therapy. Curr Probl Cancer 30 (2006) 7-32
8. De Castro G., Puglisi F., De Azambuja E., El Saghir N.S., and Awada A. Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the "do ut des" paradigm). Crit Rev Oncol/Hematol 59 (2006) 40-50
9. Folkman J. What is the evidence that tumours are angiogenesis dependent?. J Natl Cancer Inst 82 (1990) 4-6
10. Linderholm B., Tavelin B., Grankvist K., and Henriksson R. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16 (1998) 3121-3128
11. Linderholm B., Grankvist K., Wilking N., Johansson M., Tavelin B., and Henriksson R. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 18 (2000) 1423-1431
12. Bachelder R.E., Crago A., Chung J., Wendt M.A., Shaw L.M., Robinson G., and Mercurio A.M. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 61 (2001) 5736-5740
13. Said S.I., and Mutt V. Polypeptide with broad biological activity. Isolation from the small intestine. Science 69 (1970) 1271-1278
14. Fahrenkrug J., and Said S.I. VIP, PACAP, glucagons, and related peptides. Ann NY Acad Sci 921 (2000) 1-110
15. Moody T.W., Hill J.M., and Jensen R.T. VIP as a trophic factor in the CNS and cancer cells. Peptides 24 (2003) 163-177
16. Voice J.K., Dorsam G., Chan R.C., Grinninger C., Kong Y., and Goetzl E.J. Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide. Regul Pept 109 (2002) 199-208
17. Laburthe M., and Couvineau A. Molecular pharmacology and structure of PACAP receptors for VIP and PACAP. Regul Pept 108 (2002) 165-173
18. McCulloch D.A., MacKenzie C.J., Johnson M.S., Robertson D.N., Holland P.J., Ronaldson E., Lutz E.M., and Mitchell R. Additional signals from VPAC/PAC family receptors. Biochem Soc Trans 30 (2002) 441-446
19. Werner H., Koch Y., Fridkin M., Fahrenkrug J., and Gozes I. High levels of vasoactive intestinal peptide in human milk. Biochem Biophys Res Commun 133 (1985) 228-232
20. Eriksson M., Lind B., Uvnas-Morbeg K., and Hökfelt T. Distribution and origin of peptide-containing nerve fibres in the rat and human mammary gland. Neuroscience 70 (1996) 227-245
21. Moody T.W., Czerwinski G., Tarasova N.I., and Michejda C.J. VIP-ellipticine derivatives inhibit the growth of breast cancer cells. Life Sci 71 (2002) 1005-1014
22. Moody T.W., and Jensen R.T. Breast cancer VPAC1 receptors. Ann NY Acad Sci 1070 (2006) 436-439
23. Zia H., Hida T., Jakowlew S., Birrer M., Gozes Y., Reubi J.C., Fridkin M., Gozes I., and Moody T.W. Breast cancer growth is inhibited by VIPhybrid, a synthetic VIP receptor antagonist. Cancer Res 56 (1996) 3486-3489
24. Reubi J.C. In vitro identification of vasoactive intestinal peptide receptors in human tumours: implication for tumor imaging. J Nucl Med 36 (1995) 1846-1853
25. Waschek J.A., Richards M.L., and Bravo D.T. Differential expression of VIP/PACAP receptor genes in breast, intestinal, and pancreatic cell lines. Cancer Lett 92 (1995) 143-149
26. García-Fernández M.O., Collado B., Bodega G., Cortés J., Ruíz-Villaespesa A., Carmena M.J., and Prieto J.C. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue. Gynecol Endocrinol 20 (2005) 327-333
27. Collado B., Gutiérrez-Cañas I., Rodríguez-Henche N., Prieto J.C., and Carmena M.J. Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. Regul Pept 119 (2004) 69-75
28. Rau K.M., Kang H.Y., Cha T.L., Miller S.A., and Hung M.C. The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr-Relat Cancer 12 (2005) 511-532
29. Casibang M., Purdom S., Jacolew S., Neckers L., Zia F., Ben-Av P., Hla T., You L., Jablons D.M., and Moody T.W. Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial growth factor mRNAs in lung cancer cells. Lung Cancer 31 (2001) 203-213
30. Hu D.E., Hiley C.R., and Fan T.P. Comparative studies of the angiogenic activity of vasoactive intestinal peptide endothelins-1 and -3 and angiotensin II in a rat sponge model. Br J Pharmacol 117 (1996) 545-551
31. Gómez O., and Balsa J.A. Autocrine/paracrine action of pituitary vasoactive intestinal peptide on lactotroph hyperplasia induced by estrogen. Endocrinology 144 (2003) 4403-4409
32. Collado B., Carmena M.J., Sánchez-Chapado M., Ruíz-Villaespesa A., Bajo A.M., Fernández-Martínez A.B., Varga J.L., Schally A.V., and Prieto J.C. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog. Int J Oncol 26 (2005) 1629-1635
33. Juarranz M.G., Bolaños O., Gutiérrez-Cañas I., Lerner E.A., Robberecht P., Carmena M.J., Prieto J.C., and Rodríguez-Henche N. Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors. Cell Signal 13 (2001) 887-894
34. Chang J.T., Chen I.H., Liao C.T., Wang H.M., Hsu Y.M., Hung K.F., Lin C.J., Hsieh L.L., and Cheng A.J. A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients. Clin Biochem 35 (2002) 591-596
35. Gilman A.G. A protein binding assay for adenosine 3′-5′-cyclic monophosphate. Proc Natl Acad Sci U S A 67 (1970) 305-312
36. Kushlinskii N.E., and Gershtein E.S. Role of vascular endothelial growth factor during breast cancer. Bull Exp Biol Med 133 (2002) 521-528
37. Jin Q., Hemminki K., Enquist P., Lenner P., Grzybowska E., Klaes R., Henriksson R., Chen B., Pamula J., Pekala W., Zientek H., Rogozinska-Szczepka J., Utrecka-Hutka B., Hallmans G., and Förti A. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 11 (2005) 3647-3653
38. Sledge Jr. G.W. VEGF-targeting therapy for breast cancer. J Mammary Gland Biol Neoplasia 10 (2005) 319-323
39. Milkiewicz M., Ispanovic E., Doyle J.L., and Haas T.L. Regulators of angiogenesis and strategies for their therapeutic manipulation. Int J Biochem Cell Biol 38 (2006) 333-357
40. Pidgeon G.P., Barr M.P., Harmey J.H., Foley D.A., and Bouchier-Hayes D.J. Vascular endothelial growth factor (VEGF) upregulates Bcl-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 85 (2001) 273-278
41. Mukhopadhyay D., and Datta K. Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumours. Sem Cancer Biol 14 (2004) 123-130
42. Scott P.A., Smith K., Poulsom R., De Benedetti A., Bicknell R., and Harris A.L. Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E. Br J Cancer 77 (1998) 2120-2128
43. Hyder S.M., and Stancell G.M. Regulation of VEGF in the reproductive tract by sex-steroid hormones. Histol Histopathol 15 (2000) 325-334
44. Ing N.H. Steroid hormones regulate gene expression posttranscriptionally by altering the stabilities of messenger RNAs. Biol Reprod 72 (2005) 1290-1296
45. Eriksson M., Lindh B., Uvnäs-Moberg K., and Hökfelt T. Distribution and origin of peptide-containing nerve fibres in the rat and human mammary gland. Neuroscience 70 (1996) 227-245
46. Madsen B., Georg B., Madsen M.W., and Fahrenkrug J. Estradiol down regulates expression of vasoactive intestinal polypeptide receptor type-1 in breast cancer cell lines. Mol Cell Endocrinol 172 (2001) 203-211
47. Reubi J.C., Läderach U., Waser B., Gebbers J.O., Robberecht P., and Laissue J.A. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumours and their tissues of origin. Cancer Res 60 (2000) 3105-3112
48. Gespach C., Bawab W., Decremoux P., and Calvo F. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells. Cancer Res 48 (1998) 5079-5083
49. Akiri G., Nahari D., Finkelstein Y., Le S.I., Elroy-Stein O., and Levi B.Z. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene 17 (1998) 227-236
50. Tang Y., Nakada M.T., Rafferty P., Laraio J., McCabe F.L., Millar H., Cunningham M., Snyder L.A., Bugelski P., and Yan L. Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway. Mol Cancer Res 4 (2006) 371-378
51. Fry M.J. Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?. Breast Cancer Res 3 (2001) 304-312
52. Osborne C.K. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51 (1998) 227-238
53. Moody T.W., Leyton J., Chan D., Brenneman D.C., Fridkin M., Gelber E., Levy A., and Gozes I. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast Cancer Res Treat 68 (2001) 55-64